CoChat
Sign Up
Cited by 78

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Neuroinflammation in the pathophysiology of Parkinson’s disease and therapeutic evidence of anti-inflammatory drugs

Bassani, Taysa Bervian, Vital, Maria A.B.F., Rauh, Laryssa K.·2015·Arquivos de Neuro-Psiquiatria
DOI 10.1590/0004-282x20150057
Open this paper in CoChat — free account

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting approximately 1.6% of the population over 60 years old. The cardinal motor symptoms are the result of progressive degeneration of substantia nigra pars compacta dopaminergic neurons which are involved in the fine motor control. Currently, there is no cure for this pathology and the cause of the neurodegeneration remains unknown. Several studies suggest the involvement of neuroinflammation in the pathophysiology of PD as well as a protective effect of anti-inflammatory drugs both in animal models and epidemiological studies, although there are controversial reports. In this review, we address evidences of involvement of inflammatory process and possible therapeutic usefulness of anti-inflammatory drugs in PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1590/0004-282x20150057

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 2 references

Research works printed but not linked: 47

  1. Reichmann H, 2009, Non-motor features of Parkinson’s disease: depression and dementia, Parkinsonism Relat Disord, 15, S87, 10.1016/S1353-8020(09)70789-8 · DOI
  2. Barbosa MT, 2006, Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambuí study), Mov Disord, 21, 800, 10.1002/mds.20806 · DOI
  3. Munhoz RP, 2010, The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics, Clin Neurol Neurosurg, 112, 431, 10.1016/j.clineuro.2010.03.003 · DOI
  4. Dauer W, 2003, Parkinson’s disease: mechanisms and models, Neuron, 39, 889, 10.1016/S0896-6273(03)00568-3 · DOI · Paper page
  5. Long-Smith CM, 2009, The influence of microglia on the pathogenesis of Parkinson’s disease, Prog Neurobiol, 89, 277, 10.1016/j.pneurobio.2009.08.001 · DOI
  6. Hirsch EC, 2009, Neuroinflammation in Parkinson’s disease: a target for neuroprotection?, Lancet Neurol, 8, 382, 10.1016/S1474-4422(09)70062-6 · DOI · Paper page
  7. Singh N, 2007, Advances in the treatment of Parkinson’s disease, Prog Neurobiol, 81, 29, 10.1016/j.pneurobio.2006.11.009 · DOI
  8. Hirsch EC, 2005, Neuroinflammatory processes in Parkinson’s disease, Parkinsonism Relat Disord, 11, S9, 10.1016/j.parkreldis.2004.10.013 · DOI
  9. Sanders LH, 2013, Oxidative damage to macromolecules in human Parkinson disease and the rotenone model, Free Radic Biol Med, 62, 111, 10.1016/j.freeradbiomed.2013.01.003 · DOI
  10. Tansey MG, 2010, Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention, Neurobiol Dis, 37, 510, 10.1016/j.nbd.2009.11.004 · DOI · Paper page
  11. Brochard V, 2009, Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease, J Clin Invest, 119, 182
  12. Hirsch EC, 2012, Neuroinflammation in Parkinson’s disease, Parkinsonism Relat Disord, 18, S210, 10.1016/S1353-8020(11)70065-7 · DOI · Paper page
  13. Hirsch EC, 2013, Pathogenesis of Parkinson’s disease, Mov Disord, 28, 24, 10.1002/mds.25032 · DOI · Paper page
  14. Witte ME, 2010, Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration?, Mitochondrion, 10, 411, 10.1016/j.mito.2010.05.014 · DOI
  15. Ghosh A, 2007, Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease, Proc Natl Acad Sci USA, 104, 18754, 10.1073/pnas.0704908104 · DOI
  16. Mondal S, 2012, Testing NF-kB-based therapy in hemiparkinsonian monkeys, J Neuroimmune Pharmacol, 7, 544, 10.1007/s11481-012-9377-9 · DOI
  17. Wilms H, 2003, Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson´s disease, FASEB J, 17, 500, 10.1096/fj.02-0314fje · DOI
  18. Zhang F, 2010, Inhibition of lkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity, JPET, 333, 822, 10.1124/jpet.110.165829 · DOI
  19. Lima MMS, 2006, Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats, Brain Res, 1101, 117, 10.1016/j.brainres.2006.05.016 · DOI
  20. Hald A, 2005, Oxidative stress and inflammation in Parkinson’s disease: Is there a causal link?, Exp Neurol, 193, 279, 10.1016/j.expneurol.2005.01.013 · DOI
  21. Tansey MG, 2007, Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention, Exp Neurol, 208, 1, 10.1016/j.expneurol.2007.07.004 · DOI
  22. Collins LM, 2012, Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease, Neuropharmacology, 62, 2154, 10.1016/j.neuropharm.2012.01.028 · DOI · Paper page
  23. Castaño A, 2002, The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alfa, IL-1beta and IFN-gamma, J Neurochem, 81, 150, 10.1046/j.1471-4159.2002.00799.x · DOI
  24. Kurkowska-Jastrzebska I, 2004, Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson’s disease, Int Immunopharmacol, 4, 1307, 10.1016/j.intimp.2004.05.006 · DOI · Paper page
  25. Pott Godoy MC, 2008, Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson’s disease, Brain, 131, 1880, 10.1093/brain/awn101 · DOI · Paper page
  26. Asanuma M, 2007, Common anti-inflammatory drugs are potentially therapeutic for Parkinson’s disease?, Exp Neurol, 206, 172, 10.1016/j.expneurol.2007.05.006 · DOI
  27. Esposito E, 2007, Non-steroidal anti-inflammatory drugs in Parkinson’s disease, Exp Neurol, 205, 295, 10.1016/j.expneurol.2007.02.008 · DOI
  28. Reksidler AB, 2007, The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats, Eur J Pharmacol, 560, 163, 10.1016/j.ejphar.2006.12.032 · DOI
  29. Zaminelli T, 2014, Antidepressant and Antioxidative Effect of Ibuprofen in the Rotenone Model of Parkinson’s Disease, Neurotox Res, 25
  30. Swiątkiewicz M, 2013, Potential neuroprotective effect of ibuprofen, insights from the mice model of Parkinson’s disease, Pharmacol Rep, 65, 1227, 10.1016/S1734-1140(13)71480-4 · DOI
  31. Barbiero JK, 2011, Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson’s disease, Behav Brain Res, 216, 186, 10.1016/j.bbr.2010.07.033 · DOI
  32. Chen H, 2003, Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease, Arch Neurol, 60, 1059, 10.1001/archneur.60.8.1059 · DOI
  33. Chen H, 2005, Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease, Ann Neurol, 58, 963, 10.1002/ana.20682 · DOI
  34. Etminan M, 2006, NSAID use and the risk of Parkinson’s disease, Curr Drug Saf, 1, 223, 10.2174/157488606777934404 · DOI
  35. Hernán MA, 2006, Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease, Neurology, 66, 1097, 10.1212/01.wnl.0000204446.82823.28 · DOI
  36. Bower JH, 2006, Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study, Neurology, 67, 494, 10.1212/01.wnl.0000227906.99570.cc · DOI
  37. Ton TG, 2006, Nonsteroidal anti-inflammatory drugs and risk of Parkinson’s disease, Mov Disord, 21, 964, 10.1002/mds.20856 · DOI
  38. Bornebroek M, 2007, Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease, Neuroepidemiology, 28, 193, 10.1159/000108110 · DOI
  39. Wahner AD, 2007, Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease, Neurology, 69, 1836, 10.1212/01.wnl.0000279519.99344.ad · DOI
  40. Etminan M, 2008, Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study, J Clin Neurosci, 15, 576, 10.1016/j.jocn.2007.02.095 · DOI
  41. Samii A, 2009, NSAID use and the risk of Parkinson’s disease: systematic review and meta-analysis of observational studies, Drugs Aging, 26, 769, 10.2165/11316780-000000000-00000 · DOI
  42. Gagne JJ, 2010, Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis, Neurology, 74, 995, 10.1212/WNL.0b013e3181d5a4a3 · DOI
  43. Rees K, 2011, Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies, Cochrane Database Syst Rev
  44. Driver JA, 2011, Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study, BMJ, 342, 10.1136/bmj.d198 · DOI
  45. Manthripragada AD, 2011, Non-steroidal anti-inflammatory drug use and the risk of Parkinson’s disease, Neuroepidemiology, 36, 155, 10.1159/000325653 · DOI
  46. Becker C, 2011, NSAID use and risk of Parkinson disease: a population-based case-control study, Eur J Neurol, 18, 1336, 10.1111/j.1468-1331.2011.03399.x · DOI
  47. Gao X, 2011, Use of ibuprofen and risk of Parkinson disease, Neurology, 76, 863, 10.1212/WNL.0b013e31820f2d79 · DOI

Cited by

Sorted by citations

See all 78

Metadata

Authors
Bassani, T. B., Vital, M. A. B. F., & Rauh, L. K.
Affiliations
  • Pontifícia Universidade Católica do Paraná, Brazil; Universidade Federal do Paraná, Brazil
  • Universidade Federal do Paraná, Brazil
  • Pontifícia Universidade Católica do Paraná, Brazil
Venue
Arquivos de Neuro-Psiquiatria
Publisher
FapUNIFESP (SciELO)
Published
2015-07
Volume
73
Issue
7
Pages
616-623
ISSN
0004-282X
DOI
10.1590/0004-282x20150057
Cited by
78
References
2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review